Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$94.0 million.

  • Viking Therapeutics' Free Cash Flow fell 32802.57% to -$94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.6 million, marking a year-over-year decrease of 20246.33%. This contributed to the annual value of -$87.8 million for FY2024, which is 1964.4% down from last year.
  • Latest data reveals that Viking Therapeutics reported Free Cash Flow of -$94.0 million as of Q3 2025, which was down 32802.57% from -$47.1 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Free Cash Flow registered a high of -$6.1 million during Q1 2024, and its lowest value of -$94.0 million during Q3 2025.
  • Its 5-year average for Free Cash Flow is -$23.7 million, with a median of -$13.5 million in 2022.
  • Per our database at Business Quant, Viking Therapeutics' Free Cash Flow skyrocketed by 7510.86% in 2024 and then plummeted by 75313.01% in 2025.
  • Viking Therapeutics' Free Cash Flow (Quarter) stood at -$12.4 million in 2021, then increased by 11.53% to -$10.9 million in 2022, then plummeted by 61.45% to -$17.6 million in 2023, then tumbled by 76.76% to -$31.2 million in 2024, then plummeted by 201.48% to -$94.0 million in 2025.
  • Its Free Cash Flow stands at -$94.0 million for Q3 2025, versus -$47.1 million for Q2 2025 and -$52.3 million for Q1 2025.